Align Technology, Inc. (ALGN) Rating Reiterated by Piper Jaffray Companies

Align Technology, Inc. (NASDAQ:ALGN)‘s stock had its “buy” rating reissued by investment analysts at Piper Jaffray Companies in a research report issued to clients and investors on Monday. They presently have a $200.00 price target on the medical equipment provider’s stock. Piper Jaffray Companies’ price objective points to a potential upside of 7.72% from the company’s current price.

A number of other research analysts also recently issued reports on ALGN. Stifel Nicolaus reiterated a “buy” rating and set a $205.00 target price (up previously from $200.00) on shares of Align Technology in a research report on Monday, August 7th. Bank of America Corporation upgraded shares of Align Technology from a “neutral” rating to a “buy” rating and boosted their target price for the company from $175.00 to $193.00 in a research report on Friday, July 28th. Leerink Swann reiterated an “outperform” rating and set a $199.00 target price (up previously from $194.00) on shares of Align Technology in a research report on Friday, July 28th. Jefferies Group LLC reiterated a “buy” rating and set a $150.00 target price on shares of Align Technology in a research report on Thursday, June 1st. Finally, Zacks Investment Research downgraded shares of Align Technology from a “strong-buy” rating to a “hold” rating in a research report on Monday, August 21st. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $176.80.

Shares of Align Technology (ALGN) opened at 185.66 on Monday. The firm has a 50-day moving average of $172.28 and a 200 day moving average of $141.67. Align Technology has a 12-month low of $83.27 and a 12-month high of $186.10. The firm has a market capitalization of $14.88 billion, a price-to-earnings ratio of 63.58 and a beta of 1.55.

Align Technology (NASDAQ:ALGN) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.85 EPS for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.12. Align Technology had a net margin of 19.18% and a return on equity of 23.87%. The company had revenue of $356.50 million for the quarter, compared to analyst estimates of $343.43 million. During the same period in the prior year, the firm posted $0.62 EPS. The company’s quarterly revenue was up 32.3% on a year-over-year basis. On average, equities research analysts expect that Align Technology will post $3.40 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Align Technology, Inc. (ALGN) Rating Reiterated by Piper Jaffray Companies” was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this story on another domain, it was illegally stolen and republished in violation of U.S. and international trademark and copyright laws. The legal version of this story can be read at https://www.themarketsdaily.com/2017/09/13/align-technology-inc-algn-rating-reiterated-by-piper-jaffray-companies.html.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schroder Investment Management Group acquired a new position in Align Technology during the second quarter worth $104,000. CENTRAL TRUST Co raised its holdings in Align Technology by 128.5% during the second quarter. CENTRAL TRUST Co now owns 697 shares of the medical equipment provider’s stock worth $105,000 after buying an additional 392 shares during the last quarter. Van ECK Associates Corp raised its holdings in Align Technology by 6.9% during the first quarter. Van ECK Associates Corp now owns 1,057 shares of the medical equipment provider’s stock worth $121,000 after buying an additional 68 shares during the last quarter. Bronfman E.L. Rothschild L.P. raised its holdings in Align Technology by 13.0% during the second quarter. Bronfman E.L. Rothschild L.P. now owns 912 shares of the medical equipment provider’s stock worth $137,000 after buying an additional 105 shares during the last quarter. Finally, BlueMountain Capital Management LLC acquired a new position in Align Technology during the second quarter worth $148,000. Hedge funds and other institutional investors own 81.72% of the company’s stock.

About Align Technology

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Analyst Recommendations for Align Technology (NASDAQ:ALGN)

Receive News & Ratings for Align Technology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply